Sugi Predict

Sugi Predict / Compounds / SCHEMBL391064

SCHEMBL391064

SCHEMBL391064

CC(C)(C)C(C(=O)O)C(N)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 4/20 0.45
▸ CYP2D6 P10635 4/20 0.45
▸ CYP2C19 P33261 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ ADRB2 P07550 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ CYP3A4 P08684 4/20 0.40
▸ GABBR2 O75899 3/20 0.40
▸ GABBR1 Q9UBS5 3/20 0.40
▸ CYP1A2 P05177 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ FFAR2 O15552 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10824277 0.81 BRD4 (0.42) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL831692 0.77 ADRB2 (0.52) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL16967416 0.77 ADRB2 (0.52) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL16967393 0.77 ADRB2 (0.52) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL5597309 0.76 CYP2C9 (0.51) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL9261826 0.76 CYP2C9 (0.51) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL4380602 0.76 PRCP (0.41) CYP2C9CYP2D6CYP2C19MEN1KMT2A
Hydrochloric Acid SCHEMBL20521974 0.75 ADRB2 (0.50) CYP2C9CYP2D6CYP2C19MEN1KMT2A
Hydrochloric Acid SCHEMBL20521971 0.75 ADRB2 (0.50) CYP2C9CYP2D6CYP2C19MEN1KMT2A
SCHEMBL390626 0.74 CYP3A4 (0.43) CYP2C9CYP2D6CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
US-9492453-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2016-11-15 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP2C9 4553/4885CYP2D6 4066/4885CYP2C19 4023/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP2C9 4553/4885CYP2D6 4066/4885CYP2C19 4023/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP2C9 4553/4885CYP2D6 4066/4885CYP2C19 4023/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP2C9 4553/4885CYP2D6 4066/4885CYP2C19 4023/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP2C9 4111/4885CYP2D6 3865/4885CYP2C19 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.